VANCOUVER, British Columbia, Canada, December 13, 2006 – OncoGenex Technologies
Inc. today announced that it has filed a registration statement with the U.S. Securities and
Exchange Commission and a preliminary prospectus with the Canadian provincial securities
regulatory authorities for a proposed initial public offering of its common shares (the “Offering”).
RBC Capital Markets will be the sole lead manager for the Offering, and the co-managers will be
Needham & Company, LLC, Lazard Capital Markets LLC, Canaccord Adams Inc. and
Susquehanna Financial Group, LLLP.
When available, a copy of the U.S. preliminary prospectus may be obtained from RBC Capital
Markets Corporation, Attention: Prospectus Department, One Liberty Plaza, 165 Broadway, New
York, New York, U.S.A., 10006, or from the U.S. Securities and Exchange Commission at
www.sec.gov. When available, a copy of the Canadian preliminary prospectus may be obtained
from RBC Capital Markets by calling (416) 842-5345 or from the Canadian Securities
Administrators at www.sedar.com.
In the United States, a registration statement relating to these securities has been filed with the
U.S. Securities and Exchange Commission, but has not yet become effective. In Canada, a
preliminary prospectus relating to these securities has been filed with the Canadian provincial
securities regulatory authorities. These securities may not be sold nor may offers to buy be
accepted prior to the time the registration statement becomes effective and a receipt for a final
prospectus is issued by the Canadian provincial securities regulatory authorities.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful. The Offering will be made only by means of a prospectus.
About OncoGenex
OncoGenex is committed to the development and commercialization of new cancer therapies that
address treatment resistance in cancer patients. OncoGenex currently has three product
candidates in development: OGX-011, OGX-427 and OGX-225. These product candidates are
designed to selectively inhibit the production of proteins that are associated with treatment
resistance and that are over-produced in response to a variety of cancer treatments.
OncoGenex’ aim in targeting these particular proteins is to disable the tumor cell’s adaptive
defenses, render the tumor cells susceptible to attack with a variety of cancer therapies including
chemotherapy, and facilitate tumor cell death.